-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Turoctocog alfa in the treatment of individuals with hemophilia A: review of quality of life data collected in Phase III trials
Stephanie Seremetis, Roshni Kulkarni, Antoine Regnault & Elena Santagostino
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 10
Acknowledgements: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Positive Phase III trial results of pomalidomide in addition to low-dose dexamethasone suggest significant improvements for relapsed or refractory multiple myeloma patients
Isaac Bruce
News and Views: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Targeted therapy for hepatocellular carcinoma: current status and future direction
Stephen L Chan, Tony Mok
Review: Clinical Trail Outcomes: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Biologic monotherapy for the treatment of rheumatoid arthritis
Andrew Taylor, Graeme Jones
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation
-
Lung cancer vaccines: a review of three ongoing trials
Sarah R Goodyear, Hossein Borghaei
Review Article: Clinical Investigation